Skip to main content

Table 3 Summary of Preclinical Efficacy of Group III mGlu Receptor Ligands

From: Targeting metabotropic glutamate receptors for novel treatments of schizophrenia

  Positive Symptom Models Negative Symptom Models Cognition Models
Group III agonist
 ACPT-I Reduced NMDAR-HL and AHL [190]
Reduced DOI-induced head twitches [190]
  
mGlu 4 agonists
 LSP1-2111 Reduced NMDAR-HL and AHL [191]
Reduced DOI-induced head twitches [191]
  
 LSP4-2022 Reduced NMDAR-HL [192]
Reduced DOI-induced head twitches [192]
Reduced MK-801-induced deficits in social interaction [192] Reduced MK-801-induced deficits in NOR [192]
mGlu 4 PAMs
 Lu AF21934 Reduced NMDAR-HL and AHL [196, 238]
Reduced DOI-induced head twitches [196, 238]
Reduced MK-801-induced deficits in social interaction [196, 238] Rescued MK-801-induced deficits in the delayed spatial alternation task [196]
Reduced MK-801-induced deficits in NOR [238]
 Lu AF32615 Reduced NMDAR-HL and AHL [196]
Reduced DOI-induced head twitches [196]
Reduced MK-801-induced deficits in social interaction [196] Rescued MK-801-induced deficits in the delayed spatial alternation task [196]
 ADX88178 Reduced NMDAR-HL [197]
Reduced DOI-induced head twitches [197]
Reduced immobility in FST [197]  
mGlu 7 agonist
 AMN082 Exacerbated NMDAR-HL [191]
No effect on AHL [191]
Exacerbated DOI-induced head twitches [191]
  
mGlu 8 agonist
 (S)-3,4-DCPG No effect on NMDAR-HL or AHL [221]